Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF

Jessica B Spencer, Emory University
Aimee S Browne, Emory University
Susannah D Copland, Duke University School of Medicine
Donna R Session, Emory University

Journal Title: Reproductive Biology and Endocrinology
Volume: Volume 8, Number 29
Publisher: BioMed Central | 2010
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/1477-7827-8-29
Permanent URL: http://pid.emory.edu/ark:/25593/fkhdt

Final published version: http://www.rbej.com/content/8/1/29

Copyright information:
©2010 Spencer et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 Generic License (http://creativecommons.org/licenses/by/2.0/), which permits distribution of derivative works, making multiple copies, distribution, public display, and publicly performance, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author.

Accessed January 7, 2018 7:25 PM EST
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF

Jessica B Spencer1*, Aimee S Browne1, Susannah D Copland2, Donna R Session1

Abstract

Background: Administration of recombinant luteinizing hormone (rLH) in controlled ovarian hyperstimulation may benefit a subpopulation of patients. However, late follicular phase administration of high doses of rLH may also reduce the size of the follicular cohort and promote monofollicular development.

Methods: To determine if rLH in late follicular development had a negative impact on follicular growth and oocyte yield, IVF patients in our practice who received rFSH and rLH for the entire stimulation were retrospectively compared with those that had the rLH discontinued at least two days prior to hCG trigger.

Results: The two groups had similar baseline characteristics before stimulation with respect to age, FSH level and antral follicle count. However, the group which had the rLH discontinued at least two days prior to their hCG shot, had a significantly higher number of oocytes retrieved, including a higher number of MII oocytes and number of 2PN embryos.

Conclusions: When using rLH for controlled ovarian hyperstimulation, administering it from the start of stimulation and stopping it in the late follicular phase, at least two days prior to hCG trigger, may increase oocyte and embryo yield.

Background

The precise benefit and use of recombinant luteinizing hormone (rLH) is still debated. It is unclear which subpopulation benefits the most (e.g. poor responders, extreme pituitary suppression, patients with anovulation). Routine administration of rLH in antagonist cycles may increase the peak serum E2 level but did not increase the number of oocytes retrieved or increase IVF pregnancy rates in one large randomized controlled trial [1]. A recent case-control study however did show a significant increase in implantation rates when rLH was used with antagonist cycles [2]. Adding rLH after day 6 of stimulation in a favorable prognosis population does not seem to improve stimulation or pregnancy rates either [3,4]. However, when an undesirable response occurs after initial stimulation with FSH alone, adding rLH rather than increasing the FSH dose may increase the number of oocytes retrieved [5] and possibly the pregnancy rate per transfer [6]. The optimal dose and timing of rLH in controlled ovarian hyperstimulation is also unclear. One efficacy study showed an increased pregnancy rate with 75 IU vs. 37.5 IU daily (31% vs. 21% respectively) [7].

While the addition of rLH may increase response in COH, very high doses of rLH (660 IU/day) in anovulatory women, who are at particular risk of ovarian hyperstimulation, may promote the growth of a single dominant follicle [8], thereby reducing her risk for ovarian hyperstimulation syndrome. It has therefore been hypothesized that high dose rLH supplementation may reduce the size of the developing follicular cohort. Late follicular phase administration of rLH in doses of 225-450 IU/day has also shown to minimize the number of developing follicles in a smaller earlier study [9].

If poor responders potentially benefit from the addition of rLH but late follicular phase administration reduces the total number of growing midsize follicles, we hypothesized that stopping rLH in late follicular development would increase the number of oocytes obtained at retrieval. We performed a retrospective review of IVF patients in our practice that were stimulated with both rFSH and rLH to determine if stopping...
the rLH at least two days prior to hCG trigger increased
the number of oocytes retrieved.

Methods

Study design

Patients who received rLH in an IVF cycle at our clinic
between 2005-2007 were identified for chart review after
IRB approval. The two groups were assessed for age,
maximum FSH level, antral follicle count (AFC), type of
stimulation (Lupron microdose co-flare versus Lupron
down regulation protocol), whether cancellation
occurred for poor response, length of stimulation, daily
FSH and rLH dose, and peak estradiol (E2) and proges-
terone (P4) levels.

Patients on GnRH antagonists were excluded. At our
center, a microdose co-flare is preceded by luteal estradiol
patches 0.1 mg applied every other day starting on
day 20 of the prior cycle. Lupron 20 units BID is then
started on day 2 of the cycle, at a concentration of 40
mcg/0.2 mL, and continued until day of hCG. The
down regulation protocol is started on day 21 of the
preceding cycle, initially at a dose of 20 units a day
(1 mg/0.2 mL) until down regulation is achieved. The
dose is then lowered to 10 units a day until day of hCG.
Patients are generally triggered with urinary hCG 10,000
units when the lead follicle is >20 mm, or two are
greater than 18 mm, with estradiol levels at approxi-
ately 200 pg/mL per follicle, preferably on day 10 of
stimulation.

Study groups

Both groups started stimulation with both rFSH and
rLH. The subjects were divided into two groups: (1)
those that had rLH stopped two or more days prior to
hCG (with only rFSH for late follicular development),
and (2) those that received rFSH and rLH until the day
of hCG trigger.

Outcome variables

Outcomes of interest included the rate of midsize folli-
cular growth (mm/day as measured by ultrasound),
number of oocytes retrieved (total and MII), number of
2PNs after fertilization, number of grade 1 embryos
available on day 3 of development, the number of embryos
available for cryopreservation on day 3, the
pregnancy rate as a measure of both positive beta hCG
per cycle start and clinical pregnancy by ultrasound per
cycle start. The vast majority of our cycles at our center
involve a cleavage stage embryo transfer on day 2 or 3,
therefore no blastocyst data is available.

Statistical analysis

The variables were assessed for distribution and consid-
ered reasonably normally distributed, therefore
continuous variables were compared with a two tailed
unpaired t-test, and proportions by Chi-square analysis
or in cases of very small numbers, a Fisher’s exact test.
Statistical analysis was performed with SAS v9.1. A p-
value of < 0.05 was considered statistically significant.

Results

56 patients were included in the study. Table 1 demon-
strates that the two groups were similar with respect to
age, day 3 FSH level, antral follicle count (AFC), type of
stimulation and cancellation rate. These characteristics
were also not significant among the patients who pro-
cceeded to egg retrieval. While the two groups were simi-
lar to each other, they were both in poor prognosis
categories: age = 37, FSH > 8 mIU/mL, and AFC < 12,
since the majority of good prognosis patients at our
clinic receive FSH alone. Consequently, nearly half of
the stimulations were with short protocol co-flares, with
a significant rate of cancellation (21-28%). The two
groups had similar lengths of stimulation, daily FSH
dose, and peak serum estradiol and progesterone levels.
However, the group which received rLH throughout the
entire stimulation (group 2), did have a small but signifi-
cantly higher daily rLH dose (119 IU/day vs. 97 IU/day,
p = 0.038).

Table 1 Subgroups baseline characteristics and outcomes

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Group 1 (N = 42)</th>
<th>Group 2 (N = 14)</th>
<th>p-val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>37.0</td>
<td>37.5</td>
<td>0.7181</td>
</tr>
<tr>
<td>Max FSH (mIU/mL)</td>
<td>9.32</td>
<td>8.75</td>
<td>0.5451</td>
</tr>
<tr>
<td>AFC (2-10 mm)</td>
<td>10.98</td>
<td>10.50</td>
<td>0.4681</td>
</tr>
<tr>
<td>#% co-flares</td>
<td>22(52.4%)</td>
<td>6(42.9%)</td>
<td>0.5322</td>
</tr>
<tr>
<td>#% cancelled</td>
<td>12(28.6%)</td>
<td>3(21.4%)</td>
<td>0.7363</td>
</tr>
<tr>
<td>Patients who proceeded to egg retrieval</td>
<td>(N = 30)</td>
<td>(N = 11)</td>
<td>p-val</td>
</tr>
<tr>
<td>Length of stimulation (days)</td>
<td>10.4</td>
<td>11.2</td>
<td>0.1661</td>
</tr>
<tr>
<td>Daily FSH dose (IU)</td>
<td>395</td>
<td>426</td>
<td>0.3811</td>
</tr>
<tr>
<td>Daily rLH dose (IU)</td>
<td>97</td>
<td>119</td>
<td>0.0381</td>
</tr>
<tr>
<td>Peak E2 (pg/mL)</td>
<td>1892</td>
<td>1629</td>
<td>0.3221</td>
</tr>
<tr>
<td>Peak P4 (ng/mL)</td>
<td>1.21</td>
<td>0.88</td>
<td>0.0991</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Group 1 (N = 11)</td>
<td>Group 2 (N = 14)</td>
<td>p-val</td>
</tr>
<tr>
<td>Midsize follicular growth (mm/day)</td>
<td>0.96</td>
<td>0.78</td>
<td>0.4141</td>
</tr>
<tr>
<td>Oocytes retrieved</td>
<td>11.4</td>
<td>7.6</td>
<td>0.0411</td>
</tr>
<tr>
<td>Number of MII</td>
<td>8.7</td>
<td>4.7</td>
<td>0.0191</td>
</tr>
<tr>
<td>Number of 2PNs</td>
<td>68</td>
<td>3.5</td>
<td>0.0061</td>
</tr>
<tr>
<td>Number of Grade 1 embryos</td>
<td>1.23</td>
<td>1.36</td>
<td>0.8171</td>
</tr>
<tr>
<td>Embryos for cryopreservation</td>
<td>1.1</td>
<td>0.5</td>
<td>0.4501</td>
</tr>
<tr>
<td>Positive hCG/cycle start</td>
<td>27.5%</td>
<td>33.3%</td>
<td>0.7263</td>
</tr>
<tr>
<td>Clinical pregnancy/cycle start</td>
<td>25.0%</td>
<td>25.0%</td>
<td>1.0003</td>
</tr>
</tbody>
</table>

Group 1 (had rLH discontinued at least two days prior to hCG trigger) and
Group 2 (had rLH continued throughout stimulation)

1 Unpaired two tailed t-test, 2 Chi-square analysis, 3 Fisher’s exact test
**Significant assuming α = 0.05
Group 1 (rLH discontinued two or more days prior to hCG trigger) had a significantly higher number of retrieved oocytes (11.4 vs. 7.6, p = 0.041), metaphase II oocytes (MIIIs) (8.7 vs 4.7, p = 0.019) and pronuclear stage embryos (2PNs) after one day of culture (6.8 vs 3.5, p = 0.006). Group 1 also had a greater number of embryos for cryopreservation but this was not statistically significant. Clinical pregnancy rates were identical in the two groups.

Discussion
Discontinuing rLH in late follicular phase development (at least two days prior to hCG) may increase the number of oocytes, MIIIs and 2PNs in poor prognosis patients. While this was demonstrated in this preliminary, small, retrospective study, a larger prospective trial may determine whether this improves pregnancy rates in this subpopulation of IVF patients. It is likely that the use of rLH in an unselected population confers no benefit in live birth rates as demonstrated by a meta-analysis involving 701 patients [10]. This was also demonstrated in a recent study of normal responders who received rLH in the early follicular phase [11]. However, it is possible that baseline or stimulation serum LH levels may help determine which group if any benefits from rLH supplementation (and possibly when during the stimulation). One study performed with oocyte donors found rLH was only beneficial in donors with serum LH levels < 1 IU/l at the start of stimulation [12].

Conclusions
When administering rLH at the beginning of controlled ovarian hyperstimulation for a poor responder, stopping the rLH and continuing FSH stimulation alone at least two days prior to hCG trigger may increase the oocyte yield at egg retrieval, possibly resulting in more MII oocytes and 2PN embryos for the patient.

Authors' details
1Division of Reproductive Endocrinology & Infertility, Department of Gynecology & Obstetrics, Emory University School of Medicine, Atlanta, GA, USA. 2Division of Reproductive Endocrinology & Infertility, Department of Obstetrics & Gynecology, Duke University School of Medicine, Durham, NC, USA.

Authors' contributions
JBS developed study design, analyzed data, statistical methods, and drafted the manuscript. ABS analyzed data, performed statistical analysis and reviewed the manuscript. SDC assembled the raw database, provided critical review and expertise. DRS developed hypothesis, study design and reviewed manuscript. All authors read and approved the final manuscript.

Authors' information
JBS is an Assistant Professor of Reproductive Endocrinology & Infertility and the Director of the Donor Egg Program at Emory University in Atlanta, GA. ASC is an Assistant Professor of Reproductive Endocrinology & Infertility at Emory University. SDC is an Assistant Professor of Reproductive Endocrinology & Infertility and the Director of the Donor Egg and Fertility Preservation Programs at Duke University in Durham, NC. DRS is an Associate Professor and Division Director of Reproductive Endocrinology & Infertility, and the IVF director at Emory University.

Competing interests
JBS, ASB and DRS declare they have no competing interests. SDC serves on the Future Fertility Leaders Advisory Board Meeting for Merck & Co., Inc.

Received: 5 February 2010 Accepted: 23 March 2010
Published: 23 March 2010

References

Cite this article as: Spencer et al. Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF. Reproductive Biology and Endocrinology 2010 8:29.